Gene set analysis of purine and pyrimidine antimetabolites cancer therapies

Pharmacogenetics and Genomics

Volumn 21, Issue 11, 2011, Pages 701-712

  Fridley, Brooke L ^a   Batzler, Anthony ^a   Li, Liang ^a   Li, Fang ^a   Matimba, Alice ^a   Jenkins, Gregory D ^a   Ji, Yuan ^a   Wang, Liewei ^a   Weinshilboum, Richard M ^a  

^a MAYO CLINIC   (United States)

Author keywords

bioinformatics; cytotoxicity; gene set enrichment analysis; mRNA expression; pharmacogenomics

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIMETABOLITE; ARABINOSIDE; CYCLIC AMP PHOSPHODIESTERASE; GEMCITABINE; GENE PRODUCT; MERCAPTOPURINE; MESSENGER RNA; NUCLEOSIDE DIPHOSPHATASE; TIOGUANINE;

ARTICLE; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; LYMPHOBLASTOID CELL LINE; NEOPLASM; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL;

ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL LINE, TUMOR; DEOXYCYTIDINE; GENES, NEOPLASM; HUMANS; NEOPLASMS; PHENOTYPE; PURINES; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; THIOGUANINE;

EID: 80054971057     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834a48a9     Document Type: Article

References (39)

1. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 2006; 6:735-741.
2. Goeman JJ, Buhlmann P. Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics 2007; 23:980-987.
3. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006; 7:55-65.
4. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008; 7:3141-3149.
5. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci USA 2010; 107:9287-9292.
6. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern cooperative oncology group trial E2297. J Clin Oncol 2002; 20: 3270-3275.
7. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006; 107:116-124.
8. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1- beta-D-arabinofuranosylcytosine. Cancer Res 1988; 48:4024-4031.
9. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 1985; 75:632-642.
10. Fawcett T. An introduction to ROC analysis. Pattern Recognition Letters 2006; 27:861-874.
11. Kindler HL. In focus: advanced pancreatic cancer. Clin Adv Hematol Oncol 2005; 3:420-422.
12. Castaigne S, Tilly H, Sigaux F, Solal Celigny P, Bordessoule D, Briere J, et al. Treatment of malignant hemopathies with aracytine in low doses. Analysis of 159 cases. Nouv Rev Fr Hematol 1985; 27:377-382.
13. Braess J, Jahns-Streubel G, Schoch C, Haase D, Haferlach T, Fiegl M, et al. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br J Haematol 2001; 113:975-982.
14. Schoch C, Haferlach T, Haase D, Fonatsch C, Loffler H, Schlegelberger B, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112:118-126.
15. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 (Suppl 5):v7-v12.
16. Seve P, Mackey JR, Isaac S, Tredan O, Souquet PJ, Perol M, et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 2005; 49:363-370.
17. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10:1318-1325.
18. Smid K, Bergman AM, Eijk PP, Veerman G, van Haperen VW, van den Ijssel P, et al. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids 2006; 25:1001-1007.
19. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43:329-339.
20. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25:1629-1638.
21. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18:395-400.
22. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008; 68:7050-7058.
23. Li F, Fridley BL, Matimba A, Kalari KR, Pelleymounter L, Moon I, et al. Ecto-50-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos 2010; 38:2329-2338.
24. Ritz C, Streibig JC. Bioassay Analysis using R. Journal of StatisticalSoftware 2005; 12:1-22.
25. Gallant AR. Nonlinear Statistical Models. New York: Wiley; 1987
26. Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. New York: Chapman & Hall; 1995.
27. Wu Z, Irizarry R, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligobucleotide expression arrays. J Am Statistical Association 2004; 99:909-917.
28. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19:185-193.
29. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004; 20:93-99.
30. Fridley BL, Jenkins GD, Biernacka JM. Self-contained gene-set analysis of expression data: an evaluation of existing and novel methods. PLoS One 2010; 5:e12693.
31. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, Wang L. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 2009; 4: e7765.
32. Huang L, Chen CH. Proteasome regulators: activators and inhibitors. Curr Med Chem 2009; 16:931-939.
33. Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, Lazo JS. Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 2009; 76:1246-1255.
34. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8:24-36.
35. Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 2002; 4:E14.
36. Huai Q, Colicelli J, Ke H. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 2003; 42:13220-13226.
37. Nemoz G, Zhang R, Sette C, Conti M. Identification of cyclic AMPphosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett 1996; 384:97-102.
38. Carmel R, Jacobson DW. Homocysteine in Health and Disease. New York, NY: Cambridge University Press; 2001.
39. Ross CJ, Katzov-Eckert H, Dube MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41:1345-1349.